Aims: Concizumab, a humanized monoclonal antibody against tissue factor pathway inhibitor (TFPI), is being developed as a subcutaneously (s.c.) administered treatment for haemophilia. It demonstrated a concentrationdependent procoagulant effect in functional TFPI assays; however, global haemostatic assays, such as the thrombin generation assay (TGA), offer a more complete picture of coagulation. We investigated how concizumab affects thrombin generation following ex vivo spiking in plasma from haemophilia patients using the TGA, and if the assay can detect the effect of multiple s.c. concizumab doses in healthy subjects. Methods: For the ex vivo spiking study, platelet-poor plasma (PPP) from 18 patients with severe haemophilia was spiked with 0.001-500 nM concizumab. For the multiple-dosing study, four healthy males received concizumab 250 lg kg À1 s.c. every other day for eight doses; blood was collected before and after dosing and processed into PPP. In both studies, thrombin generation was measured using a Calibrated Automated Thrombogram â system with 1 pM tissue factor. Results: In spiked samples from haemophilia patients, peak thrombin and endogenous thrombin potential (ETP) increased concentration dependently, reaching near-normal levels at concizumab concentrations >10 nM. Repeated s.c. doses of concizumab in healthy subjects increased both peak thrombin and ETP; these effects were sustained throughout the dosing interval. Conclusions: Thrombin generation assay demonstrated increased thrombin generation with concizumab after ex vivo spiking of haemophilia plasma and multiple s.c. doses in healthy subjects, supporting both the utility of the TGA in evaluating concizumab treatment and the potential of s.c. concizumab as a novel haemophilia therapy.
Introduction
Severe haemophilia A and B are characterized by recurrent bleeding into joints, muscles and soft tissues [1] [2] [3] .
Primary prophylaxis with infusions of coagulation factor VIII (FVIII; haemophilia A) or factor IX (FIX; haemophilia B) is the gold standard of care for haemophilia patients today, with the aim of preventing bleeds, slowing the progression of joint destruction and preserving musculoskeletal function [1, 2, 4, 5] .
However, there is growing interest in the development of novel, non-replacement therapies with alternative mechanisms of action and modes of administration that may improve compliance. One potential target for alternative treatment strategies is tissue factor pathway inhibitor (TFPI), the primary inhibitor of the initiation of coagulation. It binds and inhibits factor VIIa (FVIIa) in complex with tissue factor (TF), and factor Xa (FXa), with the overall effect of reduced thrombin generation and decreased blood coagulation [1, 6] .
Concizumab (mAb 2021) is a humanized monoclonal antibody against TFPI with high affinity for the Kunitz-2 domain, the binding site of FXa. In addition to preventing FXa binding to TFPI, concizumab also blocks TFPI inhibition of TF-FVIIa, resulting in increased FXa and thrombin generation in vitro [1] .
Concizumab can be administered subcutaneously (s.c.); therefore, it may represent a novel approach for prophylaxis [1] .
In preclinical studies, concizumab concentrationdependently shortened clot time under haemophilialike conditions in plasma and whole blood [7] . Furthermore, in a rabbit haemophilia model, concizumab administered intravenously (i.v.) or s.c. reduced cuticle bleeding with similar efficacy to recombinant FVIIa [7] . In the first-in-human phase I trial (explorer TM 1), i.v. and s.c. concizumab showed a favourable safety profile and demonstrated non-linear pharmacokinetics [1] . This trial also highlighted a concentration-dependent procoagulant effect of concizumab: increasing concizumab levels were associated with decreased TFPI functionality [1] . A multicentre, blinded, phase Ib multiple-dose study (explorer TM 3) in patients with haemophilia A has recently been finalized, and results are pending.
Although the functional TFPI assay used in explorer TM 1 provides valuable information about the pharmacodynamic profile of concizumab, it is specific for the ability of TFPI to inhibit FXa [7] and may not capture the entire physiological function of TFPI. The thrombin generation assay (TGA) is a global haemostatic assay that provides a more complete picture of the coagulation process [8, 9] .
We report two studies to assess the effects of concizumab on thrombin generation using the TGA. In the first study, TGA demonstrates an effect of concizumab in ex vivo spiked plasma samples; we then sought to investigate whether the TGA can be used to measure the effects of circulating concizumab following s.c. administration to healthy subjects.
Materials and methods

Ethical approval
Both studies had research ethics committee approval, and explorer TM 2 was conducted in accordance with the Declaration of Helsinki and ICH Good Clinical Practice. Written informed consent was obtained for all participants in both studies prior to trial-related activities [1] .
Study populations
Patients with haemophilia (ex vivo spiking study). In the single-centre, ex vivo spiking study, blood samples were obtained from 18 patients aged 18-60 years with severe haemophilia A (<1% FVIII; n = 9), severe haemophilia B (<1% FIX; n = 3), severe haemophilia A with FVIII inhibitors (n = 6) and 10 healthy male controls. An additional patient with severe haemophilia A was enrolled but subsequently excluded from analyses as he was unable to give enough blood for complete analysis. Haemophilia patients had not received treatment with FVIII and FIX concentrates within the previous 72 h, and healthy controls were free from aspirin, non-steroidal anti-inflammatory drugs and clopidogrel.
Healthy subjects (in vivo circulating concizumab study). Blood samples were obtained from four healthy male subjects who received concizumab during explorer TM 2 (NCT01631942), a multi-centre, openlabel, multiple-dose, phase I clinical trial. Participants in the explorer TM 2 study were enrolled at Northwick Park Hospital in the PAREXEL early phase unit in London, UK, from 26 June 2012 (first subject visit) to 4 September 2012 (last subject visit). Subjects were aged 18-65 years; key exclusion criteria were advanced atherosclerotic disease and evidence or history of thromboembolic events or risk.
Study procedures
Dosing of concizumab in healthy subjects (in vivo circulating concizumab study). Each healthy subject received a single s.c. dose of concizumab (250 lg kg À1 ) every other day from day 1 (first concizumab dose) to day 15 (last concizumab dose) for a total of eight doses. Blood samples were collected at each visit [pretrial visit (between 16 and 21 days before the first dose, depending on the subject), day 1 and every other day up to day 15] both before and after concizumab dosing and then at days 22 and 35, for a total of 19 samples.
Collection and preparation of blood samples (all subjects). Blood samples from all patients with haemophilia (ex vivo spiking study) and healthy subjects from explorer TM 2 (in vivo circulating concizumab study) were collected using minimum stasis through a 21-gauge butterfly needle into Monovette â tubes with 3.2% trisodium citrate (Sarstedt AG & Co, N€ umbrecht, Germany) and 50 lg mL À1 corn trypsin inhibitor (CTI; Haematologic Technologies Inc., Vermont, USA). Blood samples from patients with haemophilia in the ex vivo spiking study were also collected into 3.2% trisodium citrate tubes without CTI. Blood was centrifuged (at 2000 9 g for 10 min), the plasma was removed and centrifuged at 20°C to obtain platelet-poor plasma (PPP). PPP was immediately aliquoted and stored at À70°C until analysis.
Thrombin generation assay
Thrombin generation was measured using the Calibrated Automated Thrombogram â [Diagnostica Stago (SAS), Asni eres-sur-Seine, France] system with 1 pM TF and 4 lM phospholipid vesicles (PPP-Reagent LOW; Diagnostica Stago UK Ltd, Theale, UK). Fluorogenic measurement of thrombin generation was performed in 96-well plates using the Fluoroskan Ascent fluorescence plate reader (Thrombinoscope BV, Maastricht, The Netherlands) as previously described [10] . For samples spiked with concizumab ex vivo, each well contained 70 lL PPP, 10 lL concizumab or buffer/control and 20 lL PPP-Reagent LOW. Concizumab was tested at final plasma concentrations of 0, 0.004, 0.018, 0.075, 0.32, 1.33, 5.62, 23.7 and 100 nM. Additionally, a subset of samples from haemophilia patients was spiked with 0.001 nM concizumab (10 patients; patient numbers: NN01-NN010) or 500 nM concizumab (eight patients; patient numbers: NN012-NN019).
For samples from healthy subjects receiving s.c. concizumab in explorer TM 2, each well contained 80 lL PPP and 20 lL PPP-Reagent LOW.
Thrombin generation was initiated by adding 20 lL of calcium-containing fluorogenic substrate [FluCa reagent (Diagnostica Stago UK Ltd)]. The fluorescence signal was measured continuously for 60 min and converted to thrombin concentration using the Thrombinoscope software. Thrombin generation was assessed by plotting peak thrombin (nM; highest amount of thrombin generated), endogenous thrombin potential (ETP; nM min; area under the plasma concentration-time curve) and lag time (min; time to initiation of thrombin generation) against time.
Other assessments
Patients with haemophilia (ex vivo spiking study). Standard coagulation-related parameters [prothrombin time (PT), activated partial thromboplastin time (aPTT) and fibrinogen concentration] were determined from plasma of patients with haemophilia and healthy controls at an accredited coagulation laboratory [Centre for Haemostasis and Thrombosis (the Haemophilia Reference Centre), Guy's and St. Thomas NHS Foundation Trust, London, UK].
Healthy subjects (in vivo circulating concizumab study). Concizumab levels were measured using the following enzyme-linked immunosorbent assay (ELISA) procedure. TFPI was bound to the plastic surface of 96-well Nunc TM MaxiSorp TM (Thermo Fisher Scientific, Nunc A/S, Roskilde, Denmark) ELISA plates with overnight incubation at 4°C. Unbound TFPI was washed away using phosphate-buffered saline with 0.05% Tween; active binding sites were blocked using phosphate-buffered saline with 0.05% Tween and 1% bovine serum albumin. In a non-binding 96-well plate, calibrators, quality controls and test samples were incubated with 2 M acetic acid for 15-60 min at room temperature in order to separate any TFPI bound to concizumab in the plasma sample. Following this acid dissociation, calibrators, quality controls and test samples were transferred to the ELISA plate where a neutralizing Tris buffer had been added to the wells. After incubation, the ELISA plate was washed and a horseradish peroxidase-labelled anti-human IgG4-specific antibody (Southern Biotech) was added to all the wells. Following incubation and washing, 3,3 0 ,5,5 0 -Tetramethylbenzidine was used for colorimetric detection of concizumab present in the samples measuring at 450 nm with 620 nm as reference by a Sunrise TM reader (Tecan Group Ltd, M€ annedorf, Switzerland) controlled by Magellan software. The concentrations were determined using WATSON LIMS TM , ThermoFisher Scientific, UK. The response is proportional to the concentration of concizumab in a sample.
The plasma levels of TFPI not bound to concizumab (referred to in this study as 'free TFPI') were determined using the commercially available ELISA [Asserachrom â Total TFPI ELISA, Diagnostica Stago (SAS)] without any modifications to the manufacturer's instructions. The assay utilizes two monoclonal anti-TFPI antibodies: the capture antibody is a monoclonal F(ab')2 fragment against the Kunitz-2 domain of TFPI, and the detecting peroxidase-conjugated monoclonal antibody is specific for total TFPI [11] . The Asserachrom â Total TFPI ELISA measures free and lipoprotein bound, as well as intact and truncated forms of TFPI but does not measure TFPI bound to concizumab. This was demonstrated by adding increasing amounts of concizumab to normal human plasma. In the presence of a large excess of concizumab (10 lg mL
À1
) where all the TFPI should be bound to concizumab, no TFPI was detected in the ELISA (data not shown).
Results
Patients with haemophilia (ex vivo spiking study)
Patients. Demographics and baseline characteristics for the 18 patients with severe haemophilia who provided samples for the ex vivo spiking study are shown in Table 1 . In this study, patients with haemophilia and normal controls had similar ages (median age of healthy subjects, 36 years; median age of patients with haemophilia, 38 years). There were a few anomalies with regard to classifying haemophilia severity: at screening, three patients (NN001, NN013 and NN014) who were known to have severe haemophilia B (<1% FIX) had FIX levels of 1.1-2.8%, and two patients (NN005 and NN015) with a history of severe haemophilia A (<1% FVIII) had FVIII levels of 4.4% and 1.9%, respectively (Table 1) .
Standard coagulation-related parameters. Results at screening were as expected for standard coagulationrelated parameters (PT, aPTT and fibrinogen concentration [PT and fibrinogen concentration, data not shown. Data for aPTT are detailed in Table 1 
]).
Thrombin generation. Individual data for thrombin generation parameters in concizumab-spiked samples from patients with haemophilia in the absence of CTI are shown in Fig. 1 . Similar results were obtained in the presence of CTI (data not shown). Concentrationdependent increases in thrombin generation were demonstrated, based on peak thrombin generation and ETP parameters, with concizumab concentrations between 0.1 and 10 nM; these came close to maximal effect for >10 nM concizumab and reached levels nearly equivalent to those of healthy controls (Fig. 2a,  b) . These concentration-dependent increases were apparent and similar with and without CTI. Mean lag time was relatively constant (Fig. 2c ). There was a reduction in mean peak thrombin generation and mean ETP in the plasma from the healthy controls when CTI was present, as well as a slight increase in lag time (Fig. 2) .
Healthy subjects (in vivo circulating concizumab study)
Subjects. Baseline characteristics for the four healthy subjects who provided blood samples for TGA assessment of in vivo circulating concizumab are shown in Table 2 . All four patients completed the explorer TM 2 trial with no severe or unexpected adverse events including no signs of thromboembolic events.
Thrombin generation, concizumab levels and free TFPI levels. Repeated single doses of s.c. concizumab were associated with increased mean thrombin generation parameters in plasma, including peak thrombin and ETP, compared with baseline (Fig. 3a,b) . A small, expected decrease in mean lag time values was observed with repeated doses (Fig. 3c) . All thrombin generation parameters had returned to baseline by the end of the trial (20 days after the last concizumab dose). Over the course of the trial, mean concizumab levels increased and total free TFPI levels (TFPI not bound to concizumab) decreased in a corresponding manner (Fig. 3d,e) . Thrombin generation increased with concizumab levels and had a negative association with total free TFPI levels (Fig. 3) . There was also a positive relationship between concizumab exposure and both peak thrombin and ETP in plasma (Fig. 4) . All concizumab and free TFPI levels returned to baseline by the end of the trial.
Discussion
Our results show that the TGA detected thrombin generation in ex vivo plasma samples from patients with severe haemophilia after spiking with increasing concentrations of concizumab, and in plasma samples from healthy subjects receiving doses of concizumab every other day for 15 days (eight doses).
Concizumab produced concentration-dependent increases in thrombin generation in the ex vivo spiking study, as evidenced by increased peak thrombin levels and ETP. This effect was apparent in plasma from patients with haemophilia A (with and without FVIII inhibitors) and haemophilia B, and the increases in thrombin reached levels equivalent to those in plasma from healthy controls. The TGA results from four healthy subjects who received repeated single doses of s.c. concizumab (one dose every other day for eight doses) confirmed the effect of concizumab on peak thrombin levels and ETP, which were positively correlated with concizumab exposure. Thrombin generation parameters were similar in samples taken before and after dosing, indicating that the effects of concizumab were sustained throughout the dosing interval when administered every other day. The variation in thrombin generation parameters between the four healthy subjects in this study is probably explained by the substantial interindividual variation in baseline characteristics (Table 2) , which is expected with such a small sample size. Interindividual differences were also observed throughout the trial in plasma levels of concizumab (Fig. 3d) ; this might be attributable to variation in characteristics such as total vascular surface or body mass index, although it could also reflect variation in the distribution of TFPI in the different physiological pools. In contrast, interindividual variation in total free TFPI levels was considerably smaller (Fig. 3e) , presumably because binding was almost saturated.
Results from the multiple-dosing study in healthy subjects are broadly consistent with those from a previous single-dose study (explorer TM 1 [1] ), in which the pharmacodynamic effects of concizumab were evaluated in both healthy volunteers and patients with haemophilia using a TFPI functionality assay. In that study, increasing doses of concizumab were associated with increased FXa generation, which was inversely proportional to free TFPI (i.e. TFPI not bound to concizumab) as measured by ELISA. The TGA used in the current study provides a more complete measure of the procoagulant activity of concizumab and information on the dynamics of thrombin generation following repeated dosing; for example, increases in peak Fig. 3 . Mean thrombin generation, concizumab exposure and free* tissue factor pathway inhibitor (TFPI) levels in plasma from healthy male subjects (n = 4) receiving multiple (eight) doses of s.c. concizumab: (a) peak thrombin; (b) endogenous thrombin potential (ETP); (c) lag time; (d) concizumab exposure; (e) free* TFPI. Data presented as mean AE standard deviation (n = 4). Thrombin generation was measured once at the pretrial visit, once before and once after concizumab dosing every other day for 8 days from day 1 to day 15 (16 measurements in total; time points before receiving concizumab illustrated with closed symbols; open symbols represent time points postdose), and once on days 22 and 35 (two measurements). Therefore, a total of 19 thrombin generation measurements are shown for each parameter. *TFPI not bound to concizumab. thrombin and ETP occurred rapidly after the start of dosing, while free TFPI declined more gradually over the course of the 15-days dosing period as partitioning from unbound TFPI to TFPI-concizumab complexes occurred.
One aspect of the TGA assay that we investigated in the ex vivo spiking study was the effect of CTI. The addition of CTI to blood samples prior to performing TGA has been advocated [12] to prevent in vitro contact activation that may occur in assays triggered with low TF concentrations [13] . However, adding CTI to blood collection tubes on a large scale is costly, and there has been debate on whether it is always needed [14] [15] [16] . We found no major differences in peak thrombin generation, ETP or lag time when blood samples were collected with or without CTI supplementation. Our findings therefore support the growing body of evidence that CTI does not have a major effect on thrombin generation [14] [15] [16] and may not routinely be needed. As also reported in a number of studies [13, 14, 16] , we did see a reduction in peak thrombin and ETP parameters in healthy controls in the presence compared with the absence of CTI, but this effect did not extend to the haemophilia patient plasma. This could be a reflection of impaired contact activation in the haemophilia patient's plasma due to the FVIII or FIX deficiency [14] .
The ex vivo spiking study was carried out in a very controlled experimental setting, and further work is needed to determine whether CTI might be necessary for TGA assays in 'real-life' situations with suboptimal collection and preparation of samples. Additionally, our results may not be generalizable to other situations, such as mild/moderate haemophilia. It should also be noted that the inclusion of CTI may be beneficial in certain circumstances, such as when minimal concentrations of TF (≤1 pmol L À1 ) are used [14, 16, 17] or when researching the mechanisms of coagulation, where it might be necessary to evaluate thrombin generation triggered by contact activation and thrombin generation triggered by TF separately [18] . The primary mechanism of action of concizumab is TF dependent; so, when thrombin generation is initiated with TF, even with 1 pM used in this study, the impact of contact activation should be minimal. Additional studies and recommendations are needed to clarify the role of CTI further [14] .
Taken together, results from the ex vivo spiking study in patients with haemophilia, and the assessment of in vivo circulating concizumab in healthy individuals, support the potential of concizumab to increase thrombin generation in patients with haemophilia. A key potential advantage of concizumab as a novel treatment for haemophilia is s.c. administration, which is likely to Fig. 4 . Correlation between thrombin generation parameters and concizumab exposure in plasma from healthy male subjects (n = 4): (a) endogenous thrombin potential (ETP); (b) peak thrombin; (c) lag time. Thrombin generation was measured at 19 time points: once at the pretrial visit, once before and once after concizumab dosing every other day for 8 days from day 1 to day 15 (16 measurements in total), and once on days 22 and 35 (two measurements). Concizumab exposure was assessed at the same time points, with the exception of the pretrial visit. For all four subjects, their day 1 predose concizumab measurements were not measurable. Additionally, two patients did not have measurable concizumab levels at their final follow-up visits Therefore, this figure shows fewer than 19 measurements per subject overall.
improve treatment convenience and enhance both compliance and treatment outcomes [1, 7] .
A limitation of our studies is the small number of subjects. More clinical studies are needed to further explore the utility of the TGA in concizumab-treated patients with haemophilia and confirm the potential role of concizumab in haemophilia prophylaxis. Larger groups of patients with different haemophilia types will be required to evaluate whether concizumab is effective in both haemophilia A and B, with and without inhibitors. However, the spiking study, with its stringent conditions, showed trends in individual patient data that were similar for all haemophilia types analysed and small standard errors for each data point for all patients -irrespective of haemophilia type.
Conclusions
The TGA detected thrombin generation associated with concizumab in ex vivo spiked blood samples from patients with haemophilia and in samples from healthy males receiving multiple s.c. doses. When added ex vivo to plasma from individuals with severe haemophilia A or B (with or without inhibitors), concizumab restored thrombin generation to nearnormal levels. Positive effects of concizumab dosing on thrombin generation were also seen in healthy males receiving multiple doses. These findings suggest utility for the TGA in evaluating concizumab treatment and the potential of s.c. concizumab as a novel therapy for people with haemophilia.
